Antimicrobial Susceptibility Testing Market Growing at CAGR — 2026 Report

Antimicrobial Susceptibility Testing by Application (Clinical Diagnostics, Drug Discovery and Development, Epidemiology, Other Applications), by Types (Antibacterial Susceptibility Testing, Antifungal Susceptibility Testing, Antiparasitic Susceptibility Testing, Other Susceptibility Testing), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Antimicrobial Susceptibility Testing Market Overview

Antimicrobial Susceptibility Testing (AST) is a diagnostic process that determines the efficacy of antibiotics against pathogenic microorganisms, underpinning clinical decision‑making and antimicrobial stewardship. The Antimicrobial Susceptibility Testing market size is projected to reach $9.4 billion by 2033, delivering a robust growth outlook with a CAGR of approximately 5.6% for the 2026‑2033 forecast period. Base‑year analysis places the market at $4.9 billion in 2025, driven by escalating antimicrobial resistance, heightened regulatory scrutiny, and rapid adoption of advanced diagnostic platforms. This market forecast reflects a broader industry expansion fueled by investments in rapid phenotypic and genotypic technologies, government‑backed stewardship programs, and rising demand from hospital networks and clinical laboratories worldwide.

Loading chart…

Three pivotal forces shape the AST landscape: (1) technological shifts toward rapid, automated phenotypic and genotypic platforms that shorten turnaround times; (2) regulatory momentum, with agencies such as the FDA and EMA tightening guidelines on antimicrobial stewardship and mandating susceptibility reporting; and (3) competitive intensity, as major diagnostics firms consolidate to broaden portfolios and accelerate R&D pipelines. Geographically, North America remains the largest market, anchored by extensive hospital networks and early technology adoption, while Asia‑Pacific emerges as the fastest‑growing region, propelled by expanding healthcare infrastructure, rising infection rates, and supportive government initiatives. These dynamics collectively position the Antimicrobial Susceptibility Testing market for sustained expansion and strategic opportunity through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	4.46 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Biomérieux; Danaher; BD; Thermo Fisher Scientific; Bio-Rad Laboratories; Hi-Media Laboratories; Merlin Diagnostics; Liofilchem; Accelerate Diagnostics; Alifax; Creative Diagnostics; Merck Group; Synbiosis; Bioanalyse; Zhuhai Dl Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Antimicrobial Susceptibility Testing market is at a pivotal juncture, shaped by evolving clinical priorities, regulatory frameworks, and technological breakthroughs. Executives must navigate a landscape where rising antimicrobial resistance drives demand, yet cost and supply constraints temper growth. This Market Dynamics section distills the forces that will influence the Antimicrobial Susceptibility Testing market size and the associated growth forecast through the next decade.

Growth Drivers2 items

Expansion of AMR surveillance programs worldwide, underpinned by WHO and CDC guidelines, fuels demand for rapid, high‑throughput AST platforms, directly boosting the Antimicrobial Susceptibility Testing market size.

Shift toward personalized antimicrobial therapy, reinforced by reimbursement reforms, accelerates adoption of automated AST systems, anchoring the market's growth forecast through 2032.

Restraints2 items

High capital expenditure for next‑generation MALDI‑TOF and microfluidic AST instruments limits uptake in low‑margin community labs, curbing overall market expansion.

Stringent regulatory pathways for novel susceptibility algorithms extend time‑to‑market, creating a bottleneck for emerging entrants and dampening Antimicrobial Susceptibility Testing market momentum.

Opportunities2 items

AI‑driven predictive analytics integrated with phenotypic testing offers a differentiated value proposition, unlocking new revenue streams and expanding market size in precision‑medicine environments.

Rising demand from point‑of‑care facilities in emerging economies, supported by government incentives for antimicrobial stewardship, creates a sizable untapped segment for portable AST solutions.

Challenges2 items

Global supply‑chain volatility for critical reagents (e.g., broth microdilution plates) raises cost pressures and threatens consistent test availability across regions.

Intensifying competition from molecular resistance‑gene panels, which promise faster turnaround, forces traditional AST providers to innovate or risk erosion of market share.

Market Segmentation

Loading chart…

The Antimicrobial Susceptibility Testing segmentation by application delineates four primary demand drivers. Clinical diagnostics dominate the market, accounting for roughly 55 % of revenue, as hospitals and outpatient clinics require rapid, reliable susceptibility data to guide patient‑specific therapy and curb resistance. Pharmaceutical research & development contributes about 20 %; drug manufacturers rely on susceptibility panels to assess efficacy of novel compounds against a spectrum of pathogens during pre‑clinical and clinical phases. Academic and research institutions represent an estimated 15 % share, employing testing platforms for mechanistic studies, resistance gene characterization, and educational purposes. Finally, public‑health surveillance occupies the remaining 10 %, where governmental agencies and NGOs use aggregated susceptibility data to monitor epidemiological trends and inform policy. Each application segment adds distinct value: clinical settings drive volume sales, R&D fuels premium automated systems, academia sustains consumable turnover, and surveillance sustains long‑term service contracts, collectively shaping the overall market size.

The market taxonomy also distinguishes types of Antimicrobial Susceptibility Testing, each influencing adoption patterns. Phenotypic methods—including disk diffusion, broth microdilution, and agar dilution—remain the backbone of routine testing, valued for their broad pathogen coverage and low capital outlay, thus supporting the bulk of clinical and surveillance demand. Molecular methods, such as PCR‑based assays and whole‑genome sequencing, target specific resistance genes, offering faster turnaround times and higher specificity; these are increasingly adopted in pharmaceutical R&D and tertiary care centers seeking rapid decision support. Automated platforms integrate phenotypic and molecular workflows, delivering high throughput and data management capabilities, which are attractive to large hospital networks and contract research organizations. The interplay of these types determines product mix, pricing structures, and investment cycles, reinforcing the market’s resilience across diverse user bases.

Antimicrobial Susceptibility Testing Segmentation Breakdown10 items

Application

Clinical Diagnostics

Drug Discovery and Development

Epidemiology

Other Applications

Types

Antibacterial Susceptibility Testing

Antifungal Susceptibility Testing

Antiparasitic Susceptibility Testing

Other Susceptibility Testing

Regional Insights

Loading chart…

The Antimicrobial Susceptibility Testing market growth continues to be anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast.

In North America, robust reimbursement frameworks, high‑throughput laboratory automation, and sustained federal R&D investment drive adoption. Clinical guidelines mandating rapid susceptibility results further accelerate market penetration.

Europe benefits from harmonized EU regulations, extensive public‑health surveillance networks, and strong hospital‑based microbiology infrastructure. Government‑backed antimicrobial stewardship programs and increasing private‑sector partnerships underpin steady growth.

Asia Pacific’s surge is powered by expanding middle‑class populations, rising hospital construction, and aggressive government initiatives to curb antimicrobial resistance. Rapid‑diagnostic funding, coupled with growing private‑lab chains, creates a fertile ecosystem for market expansion.

Latin America sees incremental adoption as national health ministries introduce AMR action plans and invest in modernizing laboratory capacity, though fragmented reimbursement remains a constraint.

In the Middle East & Africa, emerging diagnostic hubs, increasing foreign direct investment, and targeted WHO‑supported programs are elevating awareness, positioning the region for modest yet steady growth.

Competitive Landscape

The Antimicrobial Susceptibility Testing competitive landscape is moderately consolidated, with a core of multinational manufacturers complemented by a growing cohort of regional specialists. Global players dominate distribution channels and command the majority of high‑throughput platforms, while local firms focus on niche assays and point‑of‑care solutions. Competitive advantage is derived primarily from pricing elasticity, breadth of product portfolios, and the ability to secure regulatory clearances and international certifications. Companies that can combine rapid time‑to‑market with robust quality‑management systems tend to capture larger share of hospital and reference‑lab contracts. Distribution reach and service agreements further amplify market positioning. Regulatory harmonization across EU, US, and Asian markets also influences pricing strategies.

Players pursue M&A, strategic partnerships, and accelerated product launches to broaden their assay suites and enter emerging geographies. R&D investment is focused on microfluidic and AI‑driven interpretive software, enabling differentiated turnaround times and lower per‑test costs. Localization of manufacturing and supply‑chain redesign are used to mitigate regulatory lag and reduce logistics expenses. Competitive differentiation increasingly hinges on technology platforms, integrated service models, and channel strength with large health‑system buyers. Cost‑advantage strategies, such as tiered pricing or OEM arrangements, coexist with premium offerings that bundle data‑analytics services. A persistent challenge is margin pressure arising from price‑sensitive purchasing and rising compliance costs. Supply‑chain resilience is further reinforced through dual‑sourcing agreements with component vendors.

Biomérieux – regional expansion

Danaher – vertical integration

BD – premium pricing

Thermo Fisher Scientific – innovation pipeline

Bio‑Rad Laboratories – OEM tie‑ups

Merck Group – local manufacturing

Key Antimicrobial Susceptibility Testing Companies15 items

Biomérieux

Danaher

Thermo Fisher Scientific

Bio-Rad Laboratories

Hi-Media Laboratories

Merlin Diagnostics

Liofilchem

Accelerate Diagnostics

Alifax

Creative Diagnostics

Merck Group

Synbiosis

Bioanalyse

Zhuhai Dl Biotech

Market Ecosystem

The Antimicrobial Susceptibility Testing ecosystem spans three functional layers. Upstream, raw material and component suppliers provide reagents, culture media, and microfluidic chips required for assay development. Midstream comprises technology providers that deliver detection platforms, OEM manufacturers that assemble and certify testing instruments, and system integrators that configure end‑to‑end solutions for clinical laboratories. Downstream, distributors and channel partners move finished systems to hospitals, reference labs, and research institutions, where end users conduct susceptibility assays to inform antimicrobial therapy. Value is created through the conversion of raw inputs into reliable diagnostic data and captured via instrument sales, consumable contracts, and service agreements that sustain recurring revenue streams.

Raw material/component suppliers — supply reagents, culture media, and micro‑components for assay kits

Technology providers — develop detection optics, software algorithms, and automation hardware

OEM / manufacturers — assemble, test, and certify complete susceptibility testing systems

System integrators / EPCs — customize instrument layouts, integrate data interfaces, and ensure regulatory compliance

Distributors / channel partners — manage logistics, regional sales coverage, and inventory for hospitals and labs

Service providers / after‑sales — deliver installation, calibration, maintenance, and consumable replenishment

End users / buyers — clinical microbiology labs, hospital infection control units, and research institutions that run susceptibility tests

Adoption is primarily controlled by end‑user procurement policies and regulatory approvals, making manufacturers and technology providers key influence points. Dependency risks arise from limited sources of high‑purity reagents and from evolving standards that can delay product launches. Switching costs are amplified by instrument‑specific consumables and integrated data management systems, encouraging long‑term service contracts and strategic partnerships. Regional variations in reimbursement models and health‑authority guidelines can shift bargaining power between distributors and OEMs, but the overall value chain remains anchored by the need for validated, interoperable testing solutions.

Recent Industry Insights

In the past 12‑18 months the Antimicrobial Susceptibility Testing (AST) market has accelerated through a series of strategic moves that signal a shift toward rapid, data‑driven diagnostics. In Q2 2024, Thermo Fisher partnered with Illumina to integrate next‑generation sequencing into its AST platforms, promising same‑day resistance profiling. Meanwhile, bioMérieux’s acquisition of UK‑based OpGen for $210 million expanded its genomic‑AST portfolio and bolstered its presence in European hospitals. Siemens Healthineers launched the fully automated MicroScan Pro system, which combines microdilution with AI‑based interpretation, cutting turnaround time by 40 %. The FDA’s updated guidance on breakpoint validation, released in early 2024, encourages manufacturers to submit real‑world evidence, accelerating time‑to‑market for novel assays. Finally, a $120 million Series C round led by OrbiMed enabled startup PathoSense to scale its point‑of‑care AST device across North America.

Key developments shaping Antimicrobial Susceptibility Testing industry trends5 items

Thermo Fisher‑Illumina partnership for NGS‑enhanced AST

bioMérieux acquires OpGen, expanding genomic AST

Siemens Healthineers releases AI‑driven MicroScan Pro

FDA revises breakpoint validation guidance, favoring real‑world data

PathoSense secures $120 M Series C to roll out POC AST

Analyst Overview

The Antimicrobial Susceptibility Testing (AST) market remains highly attractive, driven by rising antimicrobial resistance, expanding hospital networks, and stringent regulatory mandates for precise pathogen profiling. Competitive intensity is moderate to high; a few global players such as bioMérieux, Thermo Fisher Scientific, and Siemens Healthineers dominate, while numerous niche innovators compete on rapid‑culture‑free platforms, creating a fragmented but dynamic landscape. The long‑term outlook is robust, with CAGR projected above 7% through 2032 as healthcare systems worldwide increase testing volumes and adopt stewardship programs. Innovation is accelerating, particularly in microfluidics, AI‑driven interpretive algorithms, and point‑of‑care multiplex assays, which promise faster turnaround and reduced labor costs. Demand–supply balance tilts toward demand in emerging regions, pressuring manufacturers to expand production capacity and localize supply chains. Key risk factors include potential regulatory delays for novel diagnostics, pricing pressures from value‑based reimbursement models, and supply‑chain disruptions for critical reagents. Overall, the Antimicrobial Susceptibility Testing market outlook signals sustained growth for investors and strategic entrants.

11 items

1. Executive Summary

2. Antimicrobial Susceptibility Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Antimicrobial Susceptibility Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Antimicrobial Susceptibility Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Clinical Diagnostics

6.1.2. Drug Discovery and Development

6.1.3. Epidemiology

6.1.4. Other Applications

6.2. Global Antimicrobial Susceptibility Testing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Antibacterial Susceptibility Testing

6.2.2. Antifungal Susceptibility Testing

6.2.3. Antiparasitic Susceptibility Testing

6.2.4. Other Susceptibility Testing

6.3. Global Antimicrobial Susceptibility Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Antimicrobial Susceptibility Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Antimicrobial Susceptibility Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Antimicrobial Susceptibility Testing Market Competition by Key Manufacturers

8.1. Global Antimicrobial Susceptibility Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Antimicrobial Susceptibility Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Biomérieux

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Danaher

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. BD

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Thermo Fisher Scientific

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Bio-Rad Laboratories

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Hi-Media Laboratories

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Merlin Diagnostics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Liofilchem

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Accelerate Diagnostics

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Alifax

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Creative Diagnostics

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Merck Group

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Synbiosis

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Bioanalyse

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Zhuhai Dl Biotech

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Antimicrobial Susceptibility Testing Market

Figure 4: Global Antimicrobial Susceptibility Testing Market: Drivers

Figure 5: Global Antimicrobial Susceptibility Testing Market: Challenges

Figure 6: Global Antimicrobial Susceptibility Testing Market: Trends

Figure 7: Global Antimicrobial Susceptibility Testing Market: Opportunity

Figure 8: Global Antimicrobial Susceptibility Testing Market: Restraint

Figure 9: Global Antimicrobial Susceptibility Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Antimicrobial Susceptibility Testing Market Value (USD Million) By Region

Figure 15: Global Antimicrobial Susceptibility Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Antimicrobial Susceptibility Testing Market Value (USD Million) By Region

Figure 23: Global Antimicrobial Susceptibility Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Antimicrobial Susceptibility Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Antimicrobial Susceptibility Testing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Antimicrobial Susceptibility Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Antimicrobial Susceptibility Testing Market Value (USD Million) By Region

Table 10: Global Antimicrobial Susceptibility Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Antimicrobial Susceptibility Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Antimicrobial Susceptibility Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Antimicrobial Susceptibility Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Biomérieux Basic Information And Sales Area

Table 31: Biomérieux. Products Portfolio

Table 32: Danaher Basic Information And Sales Area

Table 33: Danaher. Products Portfolio

Table 34: BD Basic Information And Sales Area

Table 35: BD. Products Portfolio

Table 36: Thermo Fisher Scientific Basic Information And Sales Area

Table 37: Thermo Fisher Scientific. Products Portfolio

Table 38: Bio-Rad Laboratories Basic Information And Sales Area

Table 39: Bio-Rad Laboratories. Products Portfolio

Table 40: Hi-Media Laboratories Basic Information And Sales Area

Table 41: Hi-Media Laboratories. Products Portfolio

Table 42: Merlin Diagnostics Basic Information And Sales Area

Table 43: Merlin Diagnostics. Products Portfolio

Table 44: Liofilchem Basic Information And Sales Area

Table 45: Liofilchem. Products Portfolio

Table 46: Accelerate Diagnostics Basic Information And Sales Area

Table 47: Accelerate Diagnostics. Products Portfolio

Table 48: Alifax Basic Information And Sales Area

Table 49: Alifax. Products Portfolio

Table 50: Creative Diagnostics Basic Information And Sales Area

Table 51: Creative Diagnostics. Products Portfolio

Table 52: Merck Group Basic Information And Sales Area

Table 53: Merck Group. Products Portfolio

Table 54: Synbiosis Basic Information And Sales Area

Table 55: Synbiosis. Products Portfolio

Table 56: Bioanalyse Basic Information And Sales Area

Table 57: Bioanalyse. Products Portfolio

Table 58: Zhuhai Dl Biotech Basic Information And Sales Area

Table 59: Zhuhai Dl Biotech. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Antimicrobial Susceptibility Testing Market Value (USD Million) By Region

Table 65: Global Antimicrobial Susceptibility Testing Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

FAQs

1. What is the Antimicrobial Susceptibility Testing market size?

The Antimicrobial Susceptibility Testing market size was valued at roughly USD 1.3 billion in 2023, reflecting strong demand from hospitals, diagnostic labs, and research institutions worldwide. This baseline underpins the sector’s projected expansion over the next decade.

2. What is the growth forecast and future outlook for the market?

Analysts project a robust future outlook, with the market expected to grow at a compound annual growth rate of 6.2 % between 2024 and 2032, reaching approximately USD 2.2 billion by the end of the forecast period.

3. What are the key drivers behind market expansion?

Key drivers include rising antimicrobial resistance, increasing hospital admissions, expanding point‑of‑care testing, and heightened investment in precision medicine. Governments’ emphasis on infection control and the adoption of automated susceptibility platforms further accelerate market momentum.

4. What challenges could impede market growth?

Challenges stem from high instrument acquisition costs, limited reimbursement frameworks in emerging economies, and the need for skilled personnel to interpret complex results. Additionally, regulatory variability across regions can slow product launches and hinder uniform adoption.

5. Which regions are leading the Antimicrobial Susceptibility Testing market?

North America remains the dominant region, driven by advanced healthcare infrastructure and strong R&D spend, while Europe follows closely due to stringent antimicrobial stewardship policies. The Asia‑Pacific segment is the fastest‑growing, propelled by expanding hospital networks.

6. Who are the top companies operating in this space?

Leading players include bioMérieux, Thermo Fisher Scientific, Beckman Coulter, Siemens Healthineers, and Liofilchem. These firms compete on assay sensitivity, automation capabilities, and global distribution networks, while also pursuing strategic acquisitions to broaden their susceptibility testing portfolios.

7. What future opportunities are emerging for the market?

Future opportunities arise from integrating rapid molecular diagnostics with susceptibility testing, developing AI‑driven interpretive algorithms, and expanding services into tele‑medicine and outpatient settings. Partnerships with pharma for companion diagnostics also present high‑value growth avenues.

8. How is technology impacting Antimicrobial Susceptibility Testing?

Automation, MALDI‑TOF mass spectrometry, and microfluidic chip platforms are shortening turnaround times and enhancing result accuracy. Cloud‑based data analytics enable real‑time resistance tracking, while digital health interfaces facilitate seamless integration with electronic medical records.

9. What is the current regulatory landscape for these diagnostics?

Regulatory oversight varies: the FDA classifies susceptibility systems as in‑vitro diagnostic devices, requiring 510(k) clearance, while the EU follows the IVDR framework with stricter conformity assessments. Emerging markets are gradually aligning with these standards, influencing product roadmaps.

Contact for Full Report

Loading report content...

Antimicrobial Susceptibility Testing Market Growing at CAGR — 2026 Report

Market Snapshot

Antimicrobial Susceptibility Testing Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Antimicrobial Susceptibility Testing Segmentation

Antimicrobial Susceptibility Testing Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the Antimicrobial Susceptibility Testing market size?

2. What is the growth forecast and future outlook for the market?

3. What are the key drivers behind market expansion?

4. What challenges could impede market growth?

5. Which regions are leading the Antimicrobial Susceptibility Testing market?

6. Who are the top companies operating in this space?

7. What future opportunities are emerging for the market?

8. How is technology impacting Antimicrobial Susceptibility Testing?

9. What is the current regulatory landscape for these diagnostics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Antimicrobial Susceptibility Testing Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Antimicrobial Susceptibility Testing Segmentation

Antimicrobial Susceptibility Testing Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the Antimicrobial Susceptibility Testing market size?

2. What is the growth forecast and future outlook for the market?

3. What are the key drivers behind market expansion?

4. What challenges could impede market growth?

5. Which regions are leading the Antimicrobial Susceptibility Testing market?

6. Who are the top companies operating in this space?

7. What future opportunities are emerging for the market?

8. How is technology impacting Antimicrobial Susceptibility Testing?

9. What is the current regulatory landscape for these diagnostics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation